Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunvozertinib versus platinum-based doublet chemotherapy in first-line EGFR exon 20 insertion NSCLC
2022-502959-54-00Phase 3Authorised
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Sep 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of sunvozertinib, pemetrexed and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoint: Progression-free survival. Planned start Sep 2023; status: authorised.
02
Drugs
sunvozertinibpemetrexedcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-502959-54-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502959-54-00.